Phase III study, V-15-32, of gefitinib versus docetaxel in previously treated Japanese patients with non-small-cell lung cancer.

@article{Maruyama2008PhaseIS,
  title={Phase III study, V-15-32, of gefitinib versus docetaxel in previously treated Japanese patients with non-small-cell lung cancer.},
  author={Riichiroh Maruyama and Yutaka Nishiwaki and Tomohide Tamura and Nobuyuki Yamamoto and Masahiro Tsuboi and Kazuhiko Nakagawa and Tetsu Shinkai and Shunichi Negoro and Fumio Imamura and Kenji Eguchi and Koji Takeda and Akira Inoue and Keisuke Tomii and Masao Harada and N. Masuda and Haiyi Jiang and Yohji Itoh and Yukito Ichinose and Nagahiro George Saijo and Masahiro Fukuoka},
  journal={Journal of clinical oncology : official journal of the American Society of Clinical Oncology},
  year={2008},
  volume={26 26},
  pages={4244-52}
}
PURPOSE This phase III study (V-15-32) compared gefitinib (250 mg/d) with docetaxel (60 mg/m(2)) in patients (N = 489) with advanced/metastatic non-small-cell lung cancer (NSCLC) who had failed one or two chemotherapy regimens. METHODS The primary objective was to compare overall survival to demonstrate noninferiority for gefitinib relative to docetaxel… CONTINUE READING